Bender Robert & Associates Makes New Investment in Pulse Biosciences, Inc. (NASDAQ:PLSE)

Bender Robert & Associates purchased a new position in Pulse Biosciences, Inc. (NASDAQ:PLSE) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 11,590 shares of the company’s stock, valued at approximately $202,000.

A number of other hedge funds have also recently added to or reduced their stakes in the business. Charles Schwab Investment Management Inc. boosted its stake in Pulse Biosciences by 0.7% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 149,206 shares of the company’s stock worth $2,598,000 after buying an additional 1,092 shares during the last quarter. Oppenheimer & Co. Inc. acquired a new stake in Pulse Biosciences in the 4th quarter worth about $311,000. SG Americas Securities LLC acquired a new stake in Pulse Biosciences in the 4th quarter worth about $193,000. Franklin Resources Inc. acquired a new stake in Pulse Biosciences in the 3rd quarter worth about $378,000. Finally, Barclays PLC boosted its stake in Pulse Biosciences by 361.4% in the 3rd quarter. Barclays PLC now owns 30,306 shares of the company’s stock worth $530,000 after buying an additional 23,738 shares during the last quarter. 76.95% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, StockNews.com upgraded Pulse Biosciences to a “sell” rating in a report on Thursday, January 2nd.

Pulse Biosciences Stock Performance

Pulse Biosciences stock opened at $17.14 on Wednesday. The stock’s 50-day moving average is $19.29 and its 200-day moving average is $18.33. Pulse Biosciences, Inc. has a 12 month low of $6.59 and a 12 month high of $25.00.

Insider Transactions at Pulse Biosciences

In other news, Director Robert W. Duggan acquired 55,256 shares of the business’s stock in a transaction dated Friday, December 13th. The shares were bought at an average cost of $17.18 per share, for a total transaction of $949,298.08. Following the acquisition, the director now directly owns 42,328,717 shares in the company, valued at $727,207,358.06. This trade represents a 0.13 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 71.50% of the company’s stock.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.